iSpecimen Inc. (ISPC) stock

ISPCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 7/3028% below fair value

$0.71−0.03 (-3.81%)

Close on Nov 11, 2026Market cap $1.79MP/E –Yield –

Earnings

iSpecimen's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

–

Not yet scheduled

Revenue, Q2 FY2024

$2.86M

EPS, Q2 FY2024

-$0.19

Latest guidance

Issued

Oct 23, 2023 · 2 items

Quarterly results

Revenue and earnings per share from each of iSpecimen's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Source
Q2 FY2024ended Jun 30, 2024	Aug 6, 2024before the open	$2.86M	–	-$0.19	Release
Q1 FY2024ended Mar 31, 2024	May 7, 2024before the open	$2.29M	-22.4%	-$0.32	Release
Q4 FY2023ended Dec 31, 2023	Mar 14, 2024before the open	–	–	–	Release
Q3 FY2023ended Sep 30, 2023	Nov 2, 2023before the open	$2.80M	+7.7%	-$0.23	Release
Q2 FY2023ended Jun 30, 2023	Aug 2, 2023before the open	–	–	–	Release
Q1 FY2023ended Mar 31, 2023	May 4, 2023before the open	$2.95M	+18.0%	-$0.27	Release
Q4 FY2022ended Dec 31, 2022	Mar 14, 2023before the open	$3.20M	–	–	Release
Q3 FY2022ended Sep 30, 2022	Nov 8, 2022before the open	$2.60M	–	-$0.35	Release
Q2 FY2022ended Jun 30, 2022	Aug 4, 2022before the open	$2.30M	–	-$0.30	Release
Q1 FY2022ended Mar 31, 2022	May 10, 2022before the open	$2.50M	–	-$0.27	Release
Q4 FY2021ended Dec 31, 2021	Feb 17, 2022during market hours	–	–	–	Release
Q2 FY2021ended Jun 30, 2021	Aug 10, 2021before the open	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period iSpecimen guided for has been reported

Guidance vs results

The last range iSpecimen gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
Q3 FY2023	Revenue	$2.60M – $2.80M	$2.80M	Within range
Q3 FY2023	Revenue growth	+60% – +70%	+7.69%	Below range

Guidance history

Every forecast iSpecimen put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Oct 23, 2023	revenue Increase	Q3 FY2023	+60% – +70%	New
Oct 23, 2023	revenue	Q3 FY2023	$2.60M – $2.80M	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.